PIPAC for peritoneal metastases of colorectal cancer

Completed

• Conditions: Colorectal Neoplasms; Cecal Neoplasms; Peritoneal Neoplasms; Peritoneal Metastases; Peritoneal Carcinomatosis; Colorectaal Carcinoom; Appendixcarcinoom; Peritoneale Metastasen; Peritonitis Carcinomatosa

• Registration Number: NL-OMON21399
• Lead Sponsor: Catharina Hospital, Eindhoven, Netherlands

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

Eligible patients are adults who have:

a World Health Organisation (WHO) performance status of ≤1 and life expectancy >3 months;

Exclusion Criteria

See inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome is the number of patients with major toxicity, defined as grade ≥3 according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0, up to four weeks after the last ePIPAC-OX.